Genadi Iosava

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · New England Journal of Medicine · 2017 · 984 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Antonio Palumbo, Roman Hájek, Michel Delforge et al. · New England Journal of Medicine · 2012 · 739 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 438 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies

Anders Österborg, Yvonne Brandberg, Genadi Iosava et al. · Journal of Clinical Oncology · 2002 · 309 citations

Medicine, Hematology, Pharmacology +17

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +17